Download PDF
Thromb Haemost 1993; 69(04): 361-365
DOI: 10.1055/s-0038-1651612
Original Article
Coagulation
Schattauer GmbH Stuttgart

Changes in β2-Glycoprotein I Antigenicity Induced by Phospholipid Binding

Dawn R Wagenknecht
The Center for Reproduction and Transplantation Immunology, Methodist Hospital of Indiana, Indianapolis, Indiana, USA
,
John A McIntyre
The Center for Reproduction and Transplantation Immunology, Methodist Hospital of Indiana, Indianapolis, Indiana, USA
› Author Affiliations
Further Information

Publication History

Received 01 October 1992

Accepted after revision 14 December 1992

Publication Date:
05 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

β2-glycoprotein I (β2GPI) or apolipoprotein H has been described as a necessary cofactor for antiphospholipid antibody (aPA) binding in ELISA. Some investigators disagree with the β2-GPI requirement whereas data from other laboratories indicate that β2GPI, not phospholipid (PL), is the antigen for aPA. To investigate the cofactor we have produced three IgG1 monoclonal antibodies (mAb) to human β2GPI; 3G9, 1B4 and 3D11. Western blot analyses showed the mAb to bind human β2GPI (40 kDa), but no reactivity was observed with adult or fetal bovine sera. In contrast, rabbit anti-β2GPI reacted with both human and bovine sera. None of the mAb reacted with phosphatidylserine (PS) or cardiolipin (CL) by ELISA. There were no significant differences in ELISA binding to purified β2GPI when the mAb were adjusted to the same concentration. mAb 3G9 and 1B4 gave stronger signals in ELISA after β2GPI bound to PS; the increase for 3G9 was significantly greater than for 1B4 (p <0.002). mAb 3D 11 was unique inasmuch as it failed to recognize β2PGI bound to PS. In comparison, the rabbit anti-β2GPI was unaffected by PS-β2GPI binding. These observations indicate that the mAb recognize three distinct epitopes on β2GPI. The data suggest that β2GPI undergoes conformational changes subsequent to binding PL. Our findings are consistent with the hypothesis that aPA recognize a β2GPI neotope formed subsequent to binding PL.

 

  • References

  • 1 McNeil P, Chesterman CN, Krilis SA. Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol 1991; 49: 193-280
    PubMedSearch in Google Scholar
  • 2 Kushner MJ. Prospective study of anticardiolipin antibodies in stroke. Stroke 1990; 21: 295-298
    CrossrefPubMedSearch in Google Scholar
  • 3 Brey RL, Hart RG, Sherman DG, Tegeler CH. Antiphospholipid antibodies and cerebral ischemia in young people. Neurology 1990; 40: 1190-1196
    CrossrefPubMedSearch in Google Scholar
  • 4 Hamsten A, Norberg R, Bjorkholm M, de-Raire U, Holm G. Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events. Lancet 1986; 1 (8473) 113-116
    PubMedSearch in Google Scholar
  • 5 Sletnes KE, Smith P, Abdelnoor M, Arnesen H, Wisloff F. Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction and non-haemorrhage stroke. Lancet 1992; 339: 451-453
    CrossrefPubMedSearch in Google Scholar
  • 6 Costello PB, Green FA. Reactivity patterns of human anticardiolipin and other antiphospholipid antibodies in syphilitic sera. Infect Immunol 1986; 51: 771-775
    PubMedSearch in Google Scholar
  • 7 Santiago MB, Cossermelli W, Tuma MF, Pinto MN, Oliveira RM. Anticardiolipin antibodies in patients with infectious diseases. Clin Rheumatol 1989; 8: 23-28
    CrossrefPubMedSearch in Google Scholar
  • 8 Allegri F, Balestrieri G, Cattaneo R, Martinelli M, Tincani A, Barcellini W, Del Papa N, Meroni PL, Falco M, Luan FL, Valesisi G, Sinico A. The plasma cofactor and anticardiolipin antibodies. Clin Exp Rheumatol 1990; 8: 613-614
    PubMedSearch in Google Scholar
  • 9 McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120-4124
    CrossrefPubMedSearch in Google Scholar
  • 10 Galli M, Comfurius P, Maassen C, Hemker HC, De Baets MH, van Breda-Vriesman PJC, Barbui T, Zwaal RFA, Bevers EM. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544-1547
    CrossrefPubMedSearch in Google Scholar
  • 12 Matsuura E, Igarashi Y, Fugimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990; 336: 177-178
    PubMedSearch in Google Scholar
  • 13 Lozier J, Takahashi N, Putnam FW. Complete amino acid sequence of human plasma β2-glycoprotein I. Proc Natl Acad Sci USA 1984; 81: 3640-3644
    CrossrefPubMedSearch in Google Scholar
  • 14 Schousboe I. Binding of β2-Glycoprotein I to platelets: effect of adenylate cyclase activity. Thromb Res 1980; 19: 225-237
    CrossrefPubMedSearch in Google Scholar
  • 15 Wurm H. β2 Glycoprotein I (apolipoprotein H) interactions with phospholipid vesicles. Int J Biochem 1984; 16: 511-514
    CrossrefPubMedSearch in Google Scholar
  • 16 Schousboe I. β2 Glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood 1985; 66: 1086-1091
    PubMedSearch in Google Scholar
  • 17 Nimpf J, Bevers EM, Bomans PHH, Till U, Wurm H, Kostner GM, Zwaal RFA. Prothrombinase activity of human platelets is inhibited by β2-glycoprotein-I. Biochim Biophys Acta 1986; 884: 142-149
    CrossrefPubMedSearch in Google Scholar
  • 18 Oosting JD, Derksen RHWM, Entjes HTI, Bouma BN, de Groot PG. Lupus anticoagulant activity is frequently dependent on the presence of β2-glycoprotein I. Thromb Haemostas 1992; 67: 499-502
    PubMedSearch in Google Scholar
  • 19 Cohnen G. Immunochemical quantitation of β2-glycoprotein I in various diseases. J Lab Clin Med 1970; 75: 212-216
    PubMedSearch in Google Scholar
  • 20 Harris EN, Pierangeli S, Barquinero J, Ordi-Ros J. Anticardiolipin antibodies and binding of anionic phospholipids and serum protein. Lancet 1990; 336: 505-506
    CrossrefPubMedSearch in Google Scholar
  • 21 Harris EN, Pierangeli S. What is the “true” antigen for antiphospholipid antibodies?. Lancet 1990; 336: 1505
    PubMedSearch in Google Scholar
  • 22 Arvieux J, Roussel B, Jacob MC, Colomb MG. Measurement of antiphospholipid antibodies by ELISA using β2-glycoprotein I as an antigen. J Immunol Meth 1991; 143: 223-229
    CrossrefPubMedSearch in Google Scholar
  • 23 Viard JP, Amoura Z, Bach JF. Association of anti-β2 glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus. Am J Med 1992; 93: 181-186
    CrossrefPubMedSearch in Google Scholar
  • 24 Shoenfeld Y, Meroni PL. The beta-2-glycoprotein I and antiphospholipid antibodies. Workshop report. Clin Exp Rheumatol 1992; 10: 205-209
    PubMedSearch in Google Scholar
  • 25 Zola H. Monoclonal Antibodies: A Manual of Techniques. CRC Press Inc; Boca Raton, FL: 1988
    Search in Google Scholar
  • 26 Triplett DA, Brandt JT, Musgrave KA, Orr CA. The relationship between lupus anticoagulants and antibodies to phospholipid. JAMA 1988; 259: 550-554
    CrossrefPubMedSearch in Google Scholar
  • 27 Laemmli UK. Cleavage of structural proteins during assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685
    CrossrefPubMedSearch in Google Scholar
  • 28 Szewczyk B, Kozloff LM. A method for the efficient blotting of strongly basic proteins from sodium dodecyl sulfate-polyaci-ylamide gels to nitrocellulose. Anal Biochem 1985; 150: 403-407
    CrossrefPubMedSearch in Google Scholar
  • 29 SAS Institute, Inc SAS User’s Guide: Statistics. Version 5. SAS Institute; Cary, NC: 1985: 956
  • 30 Polz E, Kostner GM. The binding of β2-Glycoprotein-I to human serum lipoproteins. Distribution among density fractions. FEBS Lett 1979; 102: 183-186
    CrossrefPubMedSearch in Google Scholar
  • 31 Day JR, O’Hara PJ, Grant FJ, Lofton-Day C, Berkaw MH, Werner P, Arnaud P. Molecular cloning and sequence analysis of the cDNA endocing human apolipoprotein H (β2-glycoprotein I). Int J Clin Lab Res 1992; 21: 256-263
    CrossrefPubMedSearch in Google Scholar
  • 32 Mehdi H, Nunn N, Steel DM, Whitehead AS, Perez M, Walker L, Peeples ME. Nucleotide sequence and expression of the human gene encoding apolipoprotein H (β2-glycoprotein. I). Gene 1991; 108: 293-298
    CrossrefPubMedSearch in Google Scholar
  • 33 Matsuura E, Igarashi M, Igarashi Y, Nagae H, Ickikawa K, Yasuda T, Koike T. Molecular definition of human β2-glycoprotein I (β2-GPI) by cDNA cloning and inter-species differences of β2-GPI in alteration of anticardiolipin binding. Int Immunol 1991; 3: 1217-1221
    CrossrefPubMedSearch in Google Scholar
  • 34 Teitelbaum D, Aharoni R, Sela M, Amon R. Cross-reactions and specificities of monoclonal antibodies against myelin basic protein and against the synthetic copolymer 1. Proc Natl Acad Sci USA 1991; 88: 9528-9532
    CrossrefPubMedSearch in Google Scholar
  • 35 Galli M, Comfurius P, Barbui T, Zwaal RFA, Bevers EM. Anticoagulant activity of β2-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb Haemostas 1992; 68: 297-300
    PubMedSearch in Google Scholar